Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics, Inc. Stock News

As of September 4, 2026, Vertex Pharmaceuticals Incorporated had a $138.4 billion market capitalization, compared to the Biotechnology median of $282.4 million. Vertex Pharmaceuticals Incorporated’s stock is up 20.5% in 2026, up 0.8% in the previous five trading days and up 37.59% in the past year.

Currently, Vertex Pharmaceuticals Incorporated’s price-earnings ratio is 31.8. Vertex Pharmaceuticals Incorporated’s trailing 12-month revenue is $12.6 billion with a 35.0% net profit margin. Year-over-year quarterly sales growth most recently was 12.5%. Analysts expect adjusted earnings to reach $16.657 per share for the current fiscal year. Vertex Pharmaceuticals Incorporated does not currently pay a dividend.

As of September 4, 2026, Sarepta Therapeutics, Inc. had a $2.4 billion market cap, putting it in the 56th percentile of all stocks. Sarepta Therapeutics, Inc.’s stock is up 4.6% in 2026, up 7.9% in the previous five trading days and up 21.89% in the past year.

Currently, Sarepta Therapeutics, Inc. does not have a price-earnings ratio. Sarepta Therapeutics, Inc.’s trailing 12-month revenue is $2.0 billion with a -6.9% net profit margin. Year-over-year quarterly sales growth most recently was -34.3%. Analysts expect adjusted earnings to reach $4.438 per share for the current fiscal year. Sarepta Therapeutics, Inc. does not currently pay a dividend.

How We Compare Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Vertex Pharmaceuticals Incorporated	VRTX	F
Sarepta Therapeutics, Inc.	SRPT	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Vertex Pharmaceuticals Incorporated has a Value Score of 14, which is Ultra Expensive. Sarepta Therapeutics, Inc. has a Value Score of 41, which is Average.

The Value Stock Winner: No Clear Winner

Neither Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics or Inc. is the better investment when it comes to value.

Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Vertex Pharmaceuticals Incorporated	VRTX	A
Sarepta Therapeutics, Inc.	SRPT	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Vertex Pharmaceuticals Incorporated has a Quality Score of 88, which is Very Strong. Sarepta Therapeutics, Inc. has a Quality Score of 36, which is Weak.

The Quality Grade Winner: Vertex Pharmaceuticals Incorporated

As you can clearly see from the Quality Grade breakdown above, Vertex Pharmaceuticals Incorporated has a better overall quality grade than Sarepta Therapeutics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Vertex Pharmaceuticals Incorporated could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Vertex Pharmaceuticals Incorporated	VRTX	D
Sarepta Therapeutics, Inc.	SRPT	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Vertex Pharmaceuticals Incorporated has a Earnings Estimate Score of 23, which is Negative. Sarepta Therapeutics, Inc. has a Earnings Estimate Score of 36, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc. Grades

In addition to Value, Quality and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics or Inc. Stock?

Overall, Vertex Pharmaceuticals Incorporated stock has a Value Score of 14, Estimate Revisions Score of 23 and Quality Score of 88.

Sarepta Therapeutics, Inc. stock has a Value Score of 41, Estimate Revisions Score of 36 and Quality Score of 36.

Comparing Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.